BRIEF

on NOVACYT (EPA:ALNOV)

Novacyt launches new veterinary tests

Stock price chart of NOVACYT (EPA:ALNOV) showing fluctuations.

Novacyt, a molecular diagnostics company, has announced the launch of two new multiplex tests to detect gastrointestinal disease in dogs and cats. The unveiling took place at the London Vet Show on 14-15 November 2024. The tests have the ability to detect six pathogens using a single sample, reducing hands-on time and consumables required in the laboratory.

The genesig®PLEX kits provide results in less than three hours, facilitating rapid diagnosis for more effective veterinary treatment. Lyn Rees, CEO of Novacyt, highlights the adaptability of these tests to the needs of the veterinary sector. This launch enhances the company’s portfolio of over 200 veterinary tests.

R. P.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all NOVACYT news